$VRUS - Pharmasset, Inc.
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection.
Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication.
The company has three clinical stage product candidates, including RG7128, an HCV cytosine nucleoside polymerase inhibitor; PSI-7977, an HCV uracil nucleotide analog polymerase inhibitor, which in Phase IIb clinical trial; and PSI-938, an HCV guanine nucleotide analog polymerase inhibitor, which in Phase Ib clinical trial. It is also developing PSI-661, an HCV guanine nucleotide analog polymerase inhibitor; and PSI-7977, PSI-938, and PSI-661.
In addition, the company is developing Racivir for the treatment of human immunodeficiency virus. It has a strategic collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the development of PSI-6130 and its prodrugs, including RG7128.
The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; and Emory University. Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey. The stock ended the day trading at $104.94 per share up $3.47 or 3.42% on heaveir than average trading volune of 2.27 million.
Please keep (VRUS) Pharmasset, Inc. on your watch list on your watch list for a price move above $108.17 - $108.22 going forward on heavier than average upside volume above 2.17 million. This is stock is not a buy recommendation please do your own due diligence or get help from a professional before trading.
By: Marlin Rolle
*** Please have a close look at the charts listed below ****
In order to have an in depth view of this chart please double click.